CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Azacitidinedrug
Likely dose
Azacitidine 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00569660
NCT00569660Phase 2Completed
CompareCT.gov

Phase II Study of Azacitidine in Myelofibrosis

M.D. Anderson Cancer Center·interventional·Posted Dec 7, 2007·Updated Aug 7, 2012

In Brief

A Phase 2 clinical trial evaluating Azacitidine for Myelofibrosis. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if azacitidine can help to control MF. The safety of azacitidine in patients with Myelofibrosis (MF) will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2007
Enrollment StartJun 1, 2005
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.6 years ago

Interventions

Azacitidinedrug

75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)